Survodutide Research Information
GLP-1 / Glucagon Dual Receptor Agonist
For Metabolic & Weight Management Research
⚠️ Important: This information is for educational and research purposes only. Always consult with a qualified healthcare professional before use.
📑 Contents
🔬 What is Survodutide?
Survodutide (BI 456906) is a synthetic dual agonist of the glucagon-like peptide-1 (GLP-1) and glucagon receptors that is being developed for the treatment of obesity and type 2 diabetes. It is a 29-amino acid peptide with fatty acid conjugation for once-weekly dosing .
By activating both GLP-1 and glucagon receptors, survodutide offers a distinct mechanism of action that combines appetite suppression with increased energy expenditure . Survodutide is available in pen and freeze-dried vial formulations for research purposes.
⚡ How Survodutide Works
Survodutide works through dual receptor activation:
GLP-1 Receptor
Reduces appetite, slows gastric emptying, enhances insulin secretion
Glucagon Receptor
Increases energy expenditure and fat metabolism
Combined, these mechanisms promote reduced food intake, increased calorie burning, and improved glycemic control.
📋 Research Applications
Weight Management
Evaluated for weight reduction in individuals with obesity or overweight
Type 2 Diabetes
Assessed for glycemic control and metabolic improvements
Liver Health
Investigating effects on metabolic dysfunction-associated steatotic liver disease (MASLD)
Cardiometabolic Research
Studying effects on cardiovascular risk factors
📊 Clinical Studies
Phase 2 Clinical Trial (2025)
- Survodutide demonstrated significant weight reduction in patients with obesity at doses up to 6 mg once weekly
- Significant reductions in HbA1c, fasting glucose, and liver fat content
- Favorable safety profile with gastrointestinal side effects being the most common
Key Research Findings
- Survodutide is a dual GLP-1/glucagon receptor agonist
- Demonstrates synergistic effects on weight loss and glycemic control
- Once-weekly dosing with favorable pharmacokinetics
💉 Interactive Dosing Guide
Select your vial size and dose to see the corresponding volume, clicks, dosing frequency, and how many doses per vial:
🖊️ Step 1: Select Your Vial Size
💊 Step 2: Select Your Dose
Common research protocols: 0.5-6 mg once weekly
Vial Size
2mg Vial
Selected Dose
2 mg
Doses per Vial
1 dose
Pen Clicks
300 clicks
Volume
3.00 mL
Protocol Level
Level 2 (Standard)
Recommended Schedule
Once weekly - Clinical Protocol
⚠️ Do not change your dose unless advised by a qualified professional.
📋 Protocol Level Summary
Based on research protocols: 0.5-6 mg once weekly.
| Protocol Level | Target Dose | Frequency | 2mg Clicks | 5mg Clicks | 10mg Clicks | 15mg Clicks | Who It\'s For |
|---|---|---|---|---|---|---|---|
| Level 1 (Starting) | 0.5-1 mg | Once weekly | 75-150 clicks | 30-60 clicks | 15-30 clicks | 10-20 clicks | New users, first 4 weeks |
| Level 2 (Standard) | 2-3 mg | Once weekly | 300-450 clicks | 120-180 clicks | 60-90 clicks | 40-60 clicks | After 4 weeks, maintenance |
| Level 3 (Advanced) | 4 mg | Once weekly | 600 clicks | 240 clicks | 120 clicks | 80 clicks | If more response needed |
| Level 4 (Maximum) | 6 mg | Once weekly | 900 clicks | 360 clicks | 180 clicks | 120 clicks | Experienced users only |
⚠️ Do not change your dose unless advised by a qualified professional.
💉 Vial Users (Insulin Syringe)
Add 3mL of bacteriostatic water to your freeze-dried vial and mix gently. After reconstitution, use the table below to draw your dose:
Vial Size
2mg vial with 3mL bac water
| Dose | Frequency | Units on Syringe | Volume (mL) | Protocol Level |
|---|
⚠️ Always use a new sterile needle and syringe for each injection.
⚠️ Safety & Precautions
Survodutide has shown a manageable safety profile in clinical studies. The most common adverse events are gastrointestinal side effects, including nausea, vomiting, and diarrhea, which are typically mild-to-moderate and transient.
Do not use if you:
- Are allergic to survodutide or any ingredients
- Are pregnant or breastfeeding
- Have type 1 diabetes
⚠️ Warning: If you experience severe allergic reactions, difficulty breathing, or signs of anaphylaxis, seek immediate medical help.
📚 References
- Survodutide Research Overview. Peptide Sciences.
- Survodutide Technical Guide. Benchchem.
- Survodutide: A Dual GLP-1/Glucagon Receptor Agonist. Journal of Peptide Research.
This information is for educational and research purposes only. Always consult with a qualified healthcare professional.
Last updated: July 2026